Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,41%
1 076,13
-15,38
-1,41%
—1 091,511 090,401 090,401 073,69——
SIXC
Communications
SIXC
Communications
SIXC
-0,55%
606,74
-3,37
-0,55%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,88%
1 248,82
+10,84
+0,88%
—1 237,981 237,831 252,411 225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-1,17%
1 724,36
-20,35
-1,17%
—1 744,711 740,951 747,291 721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,72%
635,59
-4,59
-0,72%
—640,18639,92643,19634,73——
SIXR
Staples
SIXR
Staples
SIXR
-0,76%
843,15
-6,43
-0,76%
—849,58845,27851,68839,47——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,55%
216,29
-1,19
-0,55%
—217,48217,48218,16215,51——
SIXT
Technology
SIXT
Technology
SIXT
+0,08%
3 263,41
+2,72
+0,08%
—3 260,693 273,363 287,813 240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,34%
939,24
-3,21
-0,34%
—942,45939,39948,80933,98——
SIXV
Health care
SIXV
Health care
SIXV
-0,29%
1 462,56
-4,24
-0,29%
—1 466,801 464,701 467,191 458,36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,71%
2 380,40
-17,10
-0,71%
—2 397,502 395,032 412,012 370,64——
4507:TYO
Shionogi & Co Ltd
JP¥3 128,00
-1,32%
(-42,00) 1D
1 Mei, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4507...
Open
JP¥3 172
High
JP¥3 174
Low
JP¥3 112
Mkt. cap
2,78 bn
Avg. vol.
2,82 m
Volume
2,33 m
Dividend
2,11%
Quarterly dividend
JP¥16
Ex dividend date
29 Sep. 2025
P/E ratio
13,66
52-wk high
JP¥3 758
52-wk low
JP¥2 162
EPS
JP¥229
Shares outstanding
314,50 m
No. of employees
5 k
News stories
From sources across the web
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees4,96 k
Founded1878
HeadquartersOsaka, Osaka-prefektuur, Japan
SectorPharmaceutical industry
Websiteshionogi.com
Last report
30 Jan. 2026
Fiscal Period
Q3 2026
Normalized EPS / Estimate
-/ -JPY
Revenue / Estimate
147,72 mjd/ (137,88 mjd est.)JPY
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Mrt. 2025
Jun. 2025
Sep. 2025
Des. 2025
Revenue
104,67 mjd
99,78 mjd
113,18 mjd
147,72 mjd
Cost of goods sold
17,79 mjd
12,32 mjd
16,94 mjd
25,09 mjd
Cost of revenue
17,79 mjd
12,32 mjd
16,94 mjd
25,09 mjd
Research and development expenses
29,16 mjd
24,89 mjd
27,55 mjd
29,87 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
23,87 mjd
25,82 mjd
27,56 mjd
35,27 mjd
Operating expense
56,78 mjd
52,37 mjd
56,57 mjd
48,45 mjd
Total operating expenses
74,57 mjd
64,68 mjd
73,51 mjd
73,54 mjd
Operating income
30,10 mjd
35,10 mjd
39,67 mjd
74,18 mjd
Other non operating income
-1,14 mjd
-1,00 m
-
-1,00 m
EBT including unusual items
44,87 mjd
46,33 mjd
52,06 mjd
92,89 mjd
EBT excluding unusual items
53,35 mjd
46,33 mjd
52,06 mjd
93,10 mjd
Income tax expense
8,68 mjd
6,98 mjd
7,87 mjd
18,21 mjd
Effective tax rate
19,33%
15,07%
15,12%
19,60%
Other operating expenses
-2,00 mjd
1,17 mjd
979,00 m
-17,25 mjd
Net income
36,63 mjd
39,36 mjd
44,19 mjd
74,68 mjd
Net profit margin
35,00%
39,44%
39,04%
50,56%
Earnings per share
-
-
-
-
Interest and investment income
25,40 mjd
13,56 mjd
14,21 mjd
20,53 mjd
Interest expense
-
-2,33 mjd
-1,82 mjd
-1,61 mjd
Net interest expenses
25,40 mjd
11,23 mjd
12,38 mjd
18,92 mjd
Depreciation and amortization charges
-3,26 mjd
-
-485,00 m
-
EBITDA
35,30 mjd
40,11 mjd
44,83 mjd
80,21 mjd
Gain or loss from assets sale
254,00 m
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer